Table 2.
Treatment groups of diabetic neuropathic pain.
| Group number | Group name | Compound name | Doses (mg/kg) | Route | Volume (ml/kg) | Animal numbers |
|---|---|---|---|---|---|---|
| One-time acute treatment | ||||||
| 1 | Sham | N/A | N/A | N/A | N/A | 10 |
| 2 | 20% PEG600/water | Vehicle | 0 | i.p. | 2 | 10 |
| 3 | Mexiletine 30 mg/kg | Mexiletine | 30 | p.o. gavage | 2 | 10 |
| 4 | Mexiletine 40 mg/kg | Mexiletine | 40 | p.o. gavage | 2 | 10a |
| 5 | Nav1.7 blocker 30 mg/kg | CC4148 | 30 | i.p. | 2 | 10 |
| 6 | Pregabalin 30 mg/kg | Pregabalin | 30 | p.o. gavage | 2 | 10 |
| Chronic treatment for 8 weeks | ||||||
| 7 | Sham | N/A | N/A | N/A | N/A | 15b |
| 8 | Water | Vehicle | 0 | p.o. drinking | Ad libitum | 18 |
| 9 | Pregabalin 30/15/20 mg/kg | Pregabalin | 30/15/20c | p.o. drinking | Ad libitum | 12 |
aMexiletine 40 mg/kg group of rats had been dosed with Mexiletine 30 mg/kg one week prior, during week 5 to week 6 after STZ injection. bTen of the sham rats were reused from the sham group in the acute study. cPregabalin was dosed daily for 8 weeks from week 12 to week 20. Pregabalin was given at 30 mg/kg/day on day 1 and reduced to 15 mg/kg/day from day 2 onwards due to adverse side effects. After 6 weeks of treatment, the dose was increased to 20 mg/kg/day for the last two weeks of the study due to tachyphylaxis (efficacy declined with time).